Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11730222 | 0.84 | ALDH1A1 (0.42) | LMNAALDH1A1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL2503665 | 0.83 | ALDH1A1 (0.37) | LMNAALDH1A1TSHRSMN1; SMN2TDP1 | |
| SCHEMBL15922644 | 0.81 | ALDH1A1 (0.35) | LMNAALDH1A1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL1658306 | 0.80 | ALDH1A1 (0.45) | LMNAALDH1A1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL23901196 | 0.80 | LMNA (0.31) | LMNAALDH1A1PTPN1 | |
| SCHEMBL4881453 | 0.80 | ALDH1A1 (0.42) | LMNAALDH1A1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL3028361 | 0.80 | LMNA (0.40) | LMNATSHRMETAP1 | |
| SCHEMBL16828370 | 0.79 | OPRM1 (0.42) | LMNATSHR | |
| SCHEMBL20305114 | 0.78 | LMNA (0.45) | LMNAALDH1A1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL52683 | 0.78 | LMNA (0.30) | LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, LLC (US) | 2010-11-04 | — | — | US | disclosed |
| US-7799954-B2 | Dicarbonyl derivatives and methods of use | ABRAXIS BIOSCIENCE, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7674816-B2 | Substituted melatonin derivatives, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, LLC (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2125694-A2 | DICARBONYL DERIVATIVES AND METHODS OF USE | Abraxis BioScience, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1701718-A4 | SUBSTITUTED MELATONIN DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE | ABRAXIS BIOSCIENCE LLC (US) | 2009-06-24 | — | — | EP | disclosed |
| EP-1976505-A1 | COMBRETASTATIN DERIVATIVES AND RELATED THERAPEUTIC METHODS | Abraxis BioScience, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008064060-A2 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070191463-A1 | Substituted melatonin derivatives, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, INC. (CA) | 2007-08-16 | — | — | US | disclosed |
| WO-2007059118-A1 | COMBRETASTATIN DERIVATIVES AND RELATED THERAPEUTIC METHODS | ABRAXIS BIOSCIENCE, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| EP-0460950-B1 | Radicicol derivatives, their preparation and their anti-tumour activity | SANKYO CO (JP) | 1997-03-05 | — | — | EP | disclosed |
| US-5597846-A | ESTERS OF RADICICOL | SANKYO COMPANY, LIMITED (JP) | 1997-01-28 | — | — | US | disclosed |
| US-5559109-A | Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist | SANKKO COMPANY, LIMITED (JP) | 1996-09-24 | — | — | US | disclosed |
| US-5556852-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0395446-B1 | N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists | SANKYO CO (JP) | 1995-03-01 | — | — | EP | disclosed |
| US-5369106-A | N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists | SANKYO COMPANY, LIMITED (JP) | 1994-11-29 | — | — | US | disclosed |
| US-5192766-A | Platelet activating factor antagonist | SANKYO COMPANY, LIMITED (JP) | 1993-03-09 | — | — | US | disclosed |
| WO-1991018905-A1 | RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY | SANKYO COMPANY LIMITED (JP) | 1991-12-12 | — | — | WO | disclosed |
| EP-0460950-A1 | Radicicol derivatives, their preparation and their anti-tumour activity | Sankyo Company Limited (JP) | 1991-12-11 | — | — | EP | disclosed |
| EP-0395446-A2 | N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists | Sankyo Company Limited (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | LMNA 2382/4885ALDH1A1 1688/4885TSHR 4693/4885 |
| US-20100279963-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | LMNA 2382/4885ALDH1A1 1688/4885TSHR 4693/4885 |
| US-20070191463-A1 | Substituted melatonin derivatives, process for their preparation, and methods of use | MTNR1B, MTNR1A, CYP3A5 | LMNA 1448/4885ALDH1A1 892/4885TSHR 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.